The effect of testosterone replacement therapy on erythropoiesis in middle aged and aged men: a systematic review protocol

Abstract

REVIEW QUESTION/OBJECTIVE The quantitative objective is to identify the effect of testosterone replacement therapy on erythropoiesis in middle aged and aged men due to potential complications that could result. More specifically, the review question deals with the red blood cell volume as measured by hematocrit, hemoglobin, and/or red blood cell count in the selected population receiving testosterone replacement therapy. INCLUSION CRITERIA Types of participants This review will consider studies that include middle aged and aged men (aged 45 or older) with diagnosed testosterone deficiency or men who have been diagnosed with hypogonadism who are receiving testosterone replacement therapy. Participants will not be included if they have prostate cancer or breast cancer. Types of interventions This review will consider studies that evaluate red blood cell volume by measuring hematocrit and/or hemoglobin and/or red blood cell count in men aged 45 years or older receiving any type, dose, or scheduled frequency of testosterone replacement therapy compared to men not receiving testosterone replacement therapy. Types of outcomes This review will consider studies that include the following outcome measures: hematocrit and/or hemoglobin and/or red blood cell count in middle aged and aged men who have received testosterone replacement therapy due to a diagnosis of hypogonadism/testosterone deficiency. To be considered for inclusion, the studies must also provide that the participants were assessed by measurement of red blood cell volume utilizing the identified measurements to determine if erythropoiesis with resulting erythrocytosis created a state of secondary polycythemia.